Dupilumab: A review of its use in the treatment of atopic dermatitis
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Dupilumab dampens the TH2 inflammatory response, thereby improving symptoms associated with atopic dermatitis.
“This dampens the T H 2 inflammatory response, thereby improving the symptoms associated with atopic dermatitis.1,2”
From Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing. (2022) · cites this paper as [2]
Through inhibition of the IL-4Rα subunit, dupilumab prevents activation of the IL-4/IL-13 signaling cascade.
“Through inhibition of the IL-4Rα subunit, it prevents activation of the IL-4/IL-13 signaling cascade.”
From Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing. (2022) · cites this paper as [2]
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · see citing works
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M. H., Bieber, T. R. M., Rocklin, R. E., Ming, J. E., Ren, H., Kao, R., Simpson, E. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,415 · see citing works
Blauvelt, A., de Bruin-Weller, M. S., Gooderham, M., Cather, J. C., Weisman, J. D., Pariser, D. M., Simpson, E. L., Papp, K. A., Hong, H.-K., Rubel, D. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,260 · see citing works
Self-citationEczema Prevalence in the United States: Data from the 2003 National Survey of Children's Health
Shaw, T., Currie, G. P., Koudelka, C. W., & Simpson, E. L. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.251 · Cited by 721 · see citing works
The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
Brunner, P. M., Guttman‐Yassky, E., & Leung, D. Y. M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.011 · Cited by 651 · see citing works
Kakinuma, T., Nakamura, K., Wakugawa, M., Mitsui, H., Tada, Y., Saeki, H., Torii, H., Asahina, A., Onai, N., Matsushima, K., et al. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.113237 · Cited by 574 · see citing works
Thaçi, D., Simpson, E. L., Beck, L. A., Bieber, T. R. M., Blauvelt, A., Papp, K. A., Soong, W., Worm, M., Szepietowski, J. C., Sofen, H. L., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00388-8 · Cited by 573 · see citing works
Self-citationCommonality of the IL-4/IL-13 pathway in atopic diseases
Gandhi, N. A., Pirozzi, G., & Graham, N. M. H. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1298443 · Cited by 493 · see citing works
Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches
Leung, D. Y. M., & Guttman‐Yassky, E. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.08.008 · Cited by 477 · see citing works
Hamilton, J. D., Suárez‐Fariñas, M., Dhingra, N., Cardinale, I. R., Li, X., Kostić, A., Ming, J. E., Radin, A. R., Krueger, J. G., Graham, N. M. H., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.10.013 · Cited by 472 · see citing works
The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma
Zheng, T., Yu, J., Oh, M. H., & Zhu, Z. (2011) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2011.3.2.67 · Cited by 423 · see citing works
The translational revolution and use of biologics in patients with inflammatory skin diseases
Noda, S., Krueger, J. G., & Guttman‐Yassky, E. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.11.015 · Cited by 197 · see citing works
Therapeutic Protein–Drug Interactions and Implications for Drug Development
Sm, H., Zhao, H., Lee, J., Reynolds, K. S., Zhang, L., Temple, R., & Lesko, L. J. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.308 · Cited by 141 · see citing works
Fleming, P., & Drucker, A. M. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.09.052 · Cited by 130 · see citing works
Kovalenko, P., DiCioccio, A., Davis, J. D., Li, M., Ardeleanu, M., Graham, N., & Soltys, R. A. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12136 · Cited by 68 · see citing works
Bullens, D. M. A., Kasran, A., Peng, X., Lorré, K., & Ceuppens, J. L. (1998) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1998.00646.x · Cited by 44 · see citing works
Diagnosis and Management of Conjunctivitis for the Dermatologist
Gooderham, M., McDonald, J., & Papp, K. A. (2017) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475417743233 · Cited by 31 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis
Bieber, T. (2020) · Allergy · doi:10.1111/all.13954 · Cited by 382 · see citing works
JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review
Huang, I., Chung, W.-H., Wu, P., & Chen, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1068260 · Cited by 341 · see citing works
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
Virtanen, A. T., Haikarainen, T., Raivola, J., & Silvennoinen, O. (2019) · BioDrugs · doi:10.1007/s40259-019-00333-w · Cited by 284 · see citing works
Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Kaino, H., & Nagata, T. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.12.015 · Cited by 242 · see citing works
“Dupilumab, an inhibitor of both IL-4 and IL-13 signaling, is used in clinical settings.(39,40) Nemolizumab, an inhibitor of IL-31 signaling, has received attention for its antipruritic effect.”
BackgroundObesity alters pathology and treatment response in inflammatory disease
Bapat, S. P., Whitty, C., Mowery, C. T., Liang, Y., Yoo, A., Jiang, Z., Peters, M. C., Zhang, L., Vogel, I. A., Zhou, C., et al. (2022) · Nature · doi:10.1038/s41586-022-04536-0 · Cited by 240 · see citing works
Çakici, N., Sutterland, A. L., Penninx, B. W. J. H., Dalm, V. A. S. H., de Haan, L., & van Beveren, N. J. M. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.04.039 · Cited by 161 · see citing works
Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases
Biazzo, M., & Deidda, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144119 · Cited by 166 · see citing works
Pavel, A. B., Song, T., Kim, H. J., DUCA, E. D., Krueger, J. G., Dubin, C., Peng, X., Xu, H., Zhang, N., Estrada, Y. D., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.07.013 · Cited by 142 · see citing works
Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients
Espinosa, M. L., Nguyen, M. T., Aguirre, A. S., Martínez‐Escala, M. E., Kim, J., Walker, C. J., Pontes, D. S., Silverberg, J. I., Choi, J., Pro, B., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.03.050 · Cited by 133 · see citing works
Atopic Dermatitis: Identification and Management of Complicating Factors
Tamagawa‐Mineoka, R., & Katoh, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082671 · Cited by 118 · see citing works
Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis
Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Oda, M., Kabashima, K., & Nagata, T. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.004 · Cited by 107 · see citing works
Nezamololama, N., Fieldhouse, K. A., Metzger, K. C., & Gooderham, M. (2020) · Drugs in Context · doi:10.7573/dic.2020-8-5 · Cited by 106 · see citing works
Self-citationGenetics of Atopic Dermatitis: From DNA Sequence to Clinical Relevance
Løset, M., Brown, S., Saunes, M., & Hveem, K. (2019) · Dermatology · doi:10.1159/000500402 · Cited by 106 · see citing works
Bain, K. A., McDonald, E., Moffat, F., Tutino, M., Castelino, M., Barton, A. C., Cavanagh, J., Ijaz, U. Z., Siebert, S., McInnes, I. B., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18008 · Cited by 96 · see citing works
Current Insights into Immunology and Novel Therapeutics of Atopic Dermatitis
Kader, H. A., Azeem, M., Jwayed, S. A., Al-Shehhi, A., Tabassum, A., Ayoub, M. A., Hetta, . F., Waheed, Y., Iratni, R., Aldhaheri, A., et al. (2021) · Cells · doi:10.3390/cells10061392 · Cited by 95 · see citing works
Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
Zhang, Y., Xu, Q., Chen, L., Chen, J. C., Zhang, J., Zou, Y., Gong, T., & Ji, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.738907 · Cited by 88 · see citing works
Butler, É., Lundqvist, C., & Axelsson, J. B. (2020) · Microorganisms · doi:10.3390/microorganisms8071026 · Cited by 84 · see citing works
Personalized medicine—concepts, technologies, and applications in inflammatory skin diseases
Litman, T. (2019) · Apmis · doi:10.1111/apm.12934 · Cited by 81 · see citing works
“For example, the first FDA-approved biologic for treatment of moderate-to-severe AD, namely the much touted IL-4Ra inhibitor dupilumab, reports response rates in the range of 44–52% EASI 75(17) (200), comparable to the rather moderate PASI75 response rates of the first generation TNF-a targeting antibodies.”
BackgroundSchwartz, C., Moran, T., Saunders, S. P., Kaszlikowska, A., Floudas, A., Bom, J., Núñez, G., Iwakura, Y., O'Neill, L. A. J., Irvine, A. D., et al. (2019) · Allergy · doi:10.1111/all.13801 · Cited by 76 · see citing works
From Emollients to Biologicals: Targeting Atopic Dermatitis
Salvati, L., Cosmi, L., & Annunziato, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910381 · Cited by 80 · see citing works
Pathophysiology and Treatment of Pruritus in Elderly
Chung, B. Y., Um, J., Kim, J. C., Kang, S. Y., Park, C. W., & Kim, H. O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010174 · Cited by 79 · see citing works
Which Way Do We Go? Complex Interactions in Atopic Dermatitis Pathogenesis
Patrick, G. J., Archer, N. K., & Miller, L. S. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.07.006 · Cited by 71 · see citing works
Yamamura, Y., Nakashima, C., & Otsuka, A. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1342176 · Cited by 73 · see citing works
“It has shown significant efficacy in moderate to severe AD patients (88).”
BackgroundEye Complications During Dupilumab Treatment for Severe Atopic Dermatitis
Ivert, L. U., Wahlgren, C., Ivert, L. U., Lundqvist, M., & Bradley, M. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3121 · Cited by 69 · see citing works
Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study
Oosterhaven, J. A. F., Voorberg, A. N., Romeijn, G. L. E., de Bruin-Weller, M. S., & Schuttelaar, M. L. A. (2019) · The Journal of Dermatology · doi:10.1111/1346-8138.14982 · Cited by 69 · see citing works
Cutaneous T‐cell lymphoma following dupilumab use: a systematic review
Park, A., Wong, L., Lang, A., Kraus, C. N., Anderson, N., & Elsensohn, A. N. (2022) · International Journal of Dermatology · doi:10.1111/ijd.16388 · Cited by 66 · see citing works
Immunological Properties of Atopic Dermatitis-Associated Alopecia Areata
Kageyama, R., Ito, T., Hanai, S., Morishita, N., Nakazawa, S., Fujiyama, T., Honda, T., & TOKURA, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052618 · Cited by 62 · see citing works
Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update
Karakioulaki, M., Eyerich, K., & Patsatsi, A. (2023) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00832-1 · Cited by 61 · see citing works
“This subunit is shared by both IL-4 and IL-13, therefore dupilumab inhibits IL-4 and IL-13 signaling [39, 62].”
BackgroundHusein‐ElAhmed, H., & Steinhoff, M. S. (2020) · Journal of Dermatological Treatment · doi:10.1080/09546634.2020.1853024 · Cited by 58 · see citing works
“It was approved in 2017 by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to manage patients with moderate-tosevere inadequately controlled AD (12) and clinical trials have shown high efficacy and tolerability (13–15).”
BackgroundJanus kinase inhibitors for atopic dermatitis: a promising treatment modality
Cartron, A. M., Nguyen, T., Roh, Y. S., Kwatra, M. M., & Kwatra, S. G. (2021) · Clinical and Experimental Dermatology · doi:10.1111/ced.14567 · Cited by 58 · see citing works
Naclerio, R. M., Baroody, F. M., Bachert, C., Bleier, B. S., Borish, L., Brittain, E., Chupp, G. L., Fisher, A., Fokkens, W. J., Gevaert, P., et al. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.02.023 · Cited by 53 · see citing works
Bodoor, K., Al‐Qarqaz, F., Heis, L., Alfaqih, M. A., Oweis, A. O., Almomani, R., & Obeidat, M. A. (2020) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s257647 · Cited by 53 · see citing works
Novel pathogenesis of atopic dermatitis from the view of cytokines in mice and humans
Nakajima, S., Tie, D., Nomura, T., & Kabashima, K. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155664 · Cited by 52 · see citing works
Radi, G., Simonetti, O., Rizzetto, G., Diotallevi, F., Molinelli, E., & Offidani, A. (2021) · Healthcare · doi:10.3390/healthcare9111575 · Cited by 52 · see citing works
Biological Therapies for Atopic Dermatitis: A Systematic Review
Zhou, S., Qi, F., Gong, Y., Zhang, J., & Zhu, B. (2021) · Dermatology · doi:10.1159/000514535 · Cited by 55 · see citing works
Alopecia Areata in Severe Atopic Dermatitis Treated With Dupilumab
Barroso-García, B., Rial, M. J., Molina, Á., & Sastre, J. (2018) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0301 · Cited by 51 · see citing works
Ocular surface disease associated with dupilumab treatment for atopic diseases
Utine, C. A., Li, G., Asbell, P. A., Pflugfelder, S. C., & Akpek, E. K. (2020) · The Ocular Surface · doi:10.1016/j.jtos.2020.05.008 · Cited by 49 · see citing works
Jay, R., Rodger, J., & Zirwas, M. (2022) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.12.011 · Cited by 48 · see citing works
“IL: interleukin INTRODUCTION Dupilumab is a monoclonal antibody that treats atopic dermatitis by blocking interleukin (IL) 4 and IL-13 signaling.(1) Dupilumab-associated inflammatory arthritis was first reported in 2019 in 3 patients who developed seronegative arthropathy and enthesitis within 16 weeks of starting the…”
BackgroundCarugno, A., Raponi, F., Locatelli, A. G., Vezzoli, P., Gambini, D., Mercurio, M. D., Test, E. R., & Sena, P. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16552 · Cited by 47 · see citing works
Selective IL-13 inhibitors for the treatment of atopic dermatitis
Gonçalves, F., Freitas, E., & Torres, T. R. (2021) · Drugs in Context · doi:10.7573/dic.2021-1-7 · Cited by 49 · see citing works
Laska, J., Tota, M., Łacwik, J., Sędek, Ł., & Gomułka, K. (2024) · Cells · doi:10.3390/cells13161398 · Cited by 51 · see citing works
Ferrucci, S. M., Casazza, G., Angileri, L., Tavecchio, S., Germiniasi, F., Berti, E., Marzano, A. V., & Genovese, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030791 · Cited by 47 · see citing works
“interleukin (IL)‐4/IL‐13 signaling through the blockade of the IL‐4 receptor α subunit, has been recently approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of patients with moderate‐to‐severe inadequately controlled AD [6].”
Eichenfield, L. F., DiBonaventura, M., Xenakis, J. J., Lafeuille, M., Duh, M. S., Fakih, I., Levenberg, M., Cappelleri, J. C., & Sikirica, V. (2020) · Dermatology and Therapy · doi:10.1007/s13555-020-00413-8 · Cited by 46 · see citing works
Dai, X., Utsunomiya, R., Shiraishi, K., Mori, H., Muto, J., Murakami, M., & Sayama, K. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.04.002 · Cited by 45 · see citing works
Immunopathology and Immunotherapy of Inflammatory Skin Diseases
Song, A., Lee, S. E., & Kim, J. H. (2022) · Immune Network · doi:10.4110/in.2022.22.e7 · Cited by 46 · see citing works
“AA, alopecia areata; AD, atopic dermatitis; AIBD, autoimmune bullous disease; Akt, protein kinase B; BP180, bullous pemphigoid antigen 2 (BPAG2); BP230, bullous pemphigoid antigen 1 (BPAG1); BTK, Bruton's tyrosine kinase; CAAR, chimeric autoantibody receptor; DC, dendritic cells; DPCP, diphenylcyclopropenone; Dsg, des…”
BackgroundInfluentialDrug survival of dupilumab compared to cyclosporin in moderate‐to‐severe atopic dermatitis patients
Bello, G. D., Maurelli, M., Schena, D., Girolomoni, G., & Gisondi, P. (2020) · Dermatologic Therapy · doi:10.1111/dth.13979 · Cited by 39 · see citing works
“Dupilumab, the first targeted systemic therapy for AD, is a fully human IgG4, monoclonal antibody that inhibits signaling of both interleukin (IL)-4 and IL-13, key inflammatory type 2 cytokines.(6) Dupilumab is approved for subcutaneous administration every other week for the treatment of adult patients with moderate-…”
BackgroundPark, K. Y., Han, H. S., Park, J. W., Kwon, H. H., Park, G., & Seo, S. J. (2021) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.14153 · Cited by 39 · see citing works
Pruritus: A Sensory Symptom Generated in Cutaneous Immuno-Neuronal Crosstalk
Szöllősi, A. G., Oláh, A., Lisztes, E., Griger, Z., & Tóth, B. I. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.745658 · Cited by 41 · see citing works
“, 2017), and forms the basis for some of the most effective treatments of itch in AD (Ruzicka et al., 2017; Gooderham et al., 2018; Bawany et al., 2020).”
BackgroundDupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians
Muzumdar, S., Skudalski, L., Sharp, K. L., & Waldman, R. A. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00646-z · Cited by 37 · see citing works
Takemura, M., Nakahara, T., Hashimoto‐Hachiya, A., Furue, M., & Tsuji, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041169 · Cited by 36 · see citing works
Martínez‐Cabriales, S. A., Kirchhof, M. G., Constantinescu, C., Murguía-Favela, L. E., & Ramien, M. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00607-6 · Cited by 36 · see citing works
Evolution of Dupilumab-Associated Cutaneous Atypical Lymphoid Infiltrates
Sokumbi, O., Shamim, H., Davis, M. D. P., Wetter, D. A., Newman, C. C., & Comfere, N. I. (2021) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000001875 · Cited by 36 · see citing works
Cuervo, M. M., Sanclemente, G., & Barrera, L. M. (2021) · Biomédica · doi:10.7705/biomedica.5978 · Cited by 38 · see citing works
“En cuanto al uso de productos biológicos, en el momento de la selección de los pacientes aún no se había autorizado en el país el dupilumab (anticuerpo monoclonal aprobado para el tratamiento de la dermatitis atópica) (44), y solo se empleaba el omalizumab en pacientes que también presentaban asma.”
BackgroundInhibition of IL-13: A New Pathway for Atopic Dermatitis
Ratnarajah, K., Le, M., Muntyanu, A., Mathieu, S., Nigen, S., Litvinov, I. V., Jack, C. S., & Netchiporouk, E. (2020) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475420982553 · Cited by 35 · see citing works
Cost‐of‐illness of atopic dermatitis in Germany: data from dermatology routine care
Mohr, N., Naatz, M., Zeervi, L., Langenbruch, A. K., Bieber, T. R. M., Werfel, T., Wollenberg, A., & Augustin, M. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17203 · Cited by 34 · see citing works
The Implications of Pruritogens in the Pathogenesis of Atopic Dermatitis
Wong, L., Yen, Y.-T., & Lee, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137227 · Cited by 35 · see citing works
Targeting Interleukin 13 for the Treatment of Atopic Dermatitis
Lytvyn, Y., & Gooderham, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020568 · Cited by 37 · see citing works
Self-citationPredictors of nonresponse to dupilumab in patients with atopic dermatitis
Wu, J. J., Hong, C.-H., Merola, J. F., Gruben, D. C., Güler, E., Feeney, C., Bhambri, A., Myers, D. E., & DiBonaventura, M. (2022) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2022.05.025 · Cited by 33 · see citing works
Jin, M., & Yoon, J. (2018) · Immune Network · doi:10.4110/in.2018.18.e42 · Cited by 33 · see citing works
“Dupilumab, the first effective biologic targeting the IL-4/IL-13 receptor was approved by Food and Drug Administration for the treatment of moderate-to-severe AD (74).”
BackgroundMiniotti, M., Lazzarin, G., Ortoncelli, M., Mastorino, L., Ribero, S., & Leombruni, P. (2022) · Dermatologic Therapy · doi:10.1111/dth.15407 · Cited by 32 · see citing works
“A significant change has occurred when a fully human monoclonal antibody Dupilumab was approved by US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of patients with moderate-to-severe AD nonresponsive to cyclosporine or other treatments.(6) Dupilumab targets the interleuk…”
BackgroundRegulation of neutrophils in type 2 immune responses
Heeb, L. E. M., Egholm, C., Impellizzieri, D., Ridder, F., & Boyman, O. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.06.009 · Cited by 33 · see citing works
Jin, A., Pousti, B. T., Savage, K. T., Mollanazar, N. K., Lee, J. B., & Hsu, S. (2019) · JAAD Case Reports · doi:10.1016/j.jdcr.2019.07.026 · Cited by 33 · see citing works
Dupilumab in Treatment of Chronic Prurigo: A Case Series and Literature Review
Almustafa, Z. Z., Weller, K., Autenrieth, J., Maurer, M., & Metz, M. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3243 · Cited by 32 · see citing works
“In AD, dupilumab has been shown to lead to a significant reduction in disease activity, as well as to a rapid, significant and clinically relevant improvement in pruritus (7).”
BackgroundZhang, L., Chen, Z., Wang, L., & Luo, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1115083 · Cited by 35 · see citing works
Update on the role of cytokines and chemokines in canine atopic dermatitis
Tamamoto‐Mochizuki, C., Santoro, D., Saridomichelakis, M. N., Eisenschenk, M. N. C., Hensel, P., & Pucheu‐Haston, C. M. (2023) · Veterinary Dermatology · doi:10.1111/vde.13192 · Cited by 30 · see citing works
Abrocitinib for the treatment of atopic dermatitis
Crowley, E. L., Nezamololama, N., Papp, K. A., & Gooderham, M. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1828068 · Cited by 31 · see citing works
Self-citationMiniotti, M., Ribero, S., Mastorino, L., Ortoncelli, M., Gelato, F., Bailon, M., Trioni, J., Stefan, B., Quaglino, P., & Leombruni, P. (2023) · Experimental Dermatology · doi:10.1111/exd.14786 · Cited by 30 · see citing works
Linking adipose tissue eosinophils, IL-4, and leptin in human obesity and insulin resistance
Hernandez, J. D., Li, T., Ghannam, H., Rau, C. M., Masuda, M. Y., Madura, J. A., Jacobsen, E. A., & Filippis, E. D. (2024) · JCI Insight · doi:10.1172/jci.insight.170772 · Cited by 29 · see citing works
“Our findings have the potential for clinical relevance in diseases currently treated with systemic injection of monoclonal antibody against IL-4 receptors (43–46).”
Wang, Y., & Jorizzo, J. L. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.11.042 · Cited by 29 · see citing works
Hydrogels: A Promising Vehicle for the Topical Management of Atopic Dermatitis
Barbosa, A. I., Torres, T. R., Lima, S. A. C., & Reis, S. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100028 · Cited by 30 · see citing works
Takamura, S., & Teraki, Y. (2022) · The Journal of Dermatology · doi:10.1111/1346-8138.16428 · Cited by 29 · see citing works
Dupilumab in the Treatment of Chronic Rhinosinusitis with Nasal Polyposis
Boyle, J. V., Lam, K. K., & Han, J. K. (2020) · Immunotherapy · doi:10.2217/imt-2019-0191 · Cited by 30 · see citing works
A Review of Existing and New Treatments for the Management of Hand Eczema
Ho, J. S. S., & Molin, S. (2023) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/12034754231188325 · Cited by 28 · see citing works
“53 Dupilumab is a human monoclonal IgG4 antibody that inhibits IL-4 and IL-13 signal transduction by binding the shared α-subunit of the IL-4 receptor that has been shown to be effective in AD.”
BackgroundRønnstad, A. T. M., Hansen, P. M., Halling, A., Egeberg, A., Kolko, M., Heegaard, S., & Thyssen, J. P. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17832 · Cited by 29 · see citing works
Crosstalk between keratinocytes and immune cells in inflammatory skin diseases
Ni, X., & Lai, Y. (2021) · Exploration of Immunology · doi:10.37349/ei.2021.00028 · Cited by 30 · see citing works
“Dupilumab, an IL-4Rα antagonist that inhibits both IL-4 and IL-13 signaling, and tralokinumab, an IL-13 inhibitor, have been approved for the treatment of AD [98, 99].”
Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis
Li, G., Berkenstock, M., & Soiberman, U. (2020) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2020.100848 · Cited by 27 · see citing works
Peng, S., Chen, M., Yin, M., & Feng, H. (2021) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s310426 · Cited by 27 · see citing works
Hu, G.-H., & Zhou, X. (2021) · Clinical, Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s327825 · Cited by 23 · see citing works
“Our experimental results also illustrate the involvement of Th17 in AD.”
BackgroundInfluentialAgboola, F. O., Atlas, S. J., Brouwer, E., Carlson, J. J., Hansen, R. N., Herron-Smith, S., Nhan, E., Rind, D. M., & Pearson, S. D. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.1.108 · Cited by 27 · see citing works
Vitiligo induced by dupilumab treatment: A case series
Ren, H., Akabane, A. L., Kelleher, K., Halverstam, C., Hicks, M., Schachter, J. R., Silverman, R. A., Chachkin, S., Sherman‐Bergman, S., Harris, J. E., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19132 · Cited by 26 · see citing works
Development of Sézary syndrome following the administration of dupilumab
Tran, J. Q., Morris, L. M., Vu, A., & Duvic, M. A. (2020) · Dermatology Online Journal · doi:10.5070/d3264048364 · Cited by 26 · see citing works
“This inhibition of IL4 and IL13 leads to decreased cytokine-induced inflammatory responses, ultimately dampening the Th2 response and minimizing the disease activity of atopic dermatitis [1].”
InfluentialTwo Cancer Patients Receiving Dupilumab for Treatment of Atopic Dermatitis
Fowler, E., Rosen, J. D., Lev‐Tov, H. A., & Yosipovitch, G. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3201 · Cited by 26 · see citing works
Safety of dupilumab in patients with atopic dermatitis: expert opinion
Francuzik, W., Alexiou, A., & Worm, M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1939673 · Cited by 24 · see citing works
“Dupilumab is a fully human IgG4 monoclonal antibody directed against the interleukin (IL)-4 receptor α (IL-4Rα) subunit [1].”
BackgroundAppraisal of Proactive Topical Therapy in Atopic Dermatitis: Pros and Cons
Frølunde, A. S., Thyssen, J. P., Deleuran, M. S., & Vestergaard, C. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00629-0 · Cited by 25 · see citing works
Mastorino, L., Rosset, F., Gelato, F., Ortoncelli, M., Cavaliere, G., Quaglino, P., & Ribero, S. (2022) · Pharmaceuticals · doi:10.3390/ph15070883 · Cited by 25 · see citing works
Evidence-based management of keloids and hypertrophic scars in dermatology
Kim, E., Hussain, A. N., & Khachemoune, A. (2022) · Archives of Dermatological Research · doi:10.1007/s00403-022-02509-x · Cited by 25 · see citing works
Lai, Q. W. S., Fan, Q., Zheng, B. Z.-Y., Chen, Y., Dong, T. T.-X., & Tsim, K. W. K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.941413 · Cited by 24 · see citing works
“A recent FDAapproved drug Dupilumab, an antibody targeting to inhibit IL-4 and IL-13, has been adopted to treat severe AD patients; however, nearly 20% subjects experienced adverse events during phase III clinical trials of Dupilumab (Gooderham et al., 2018).”
BackgroundInfluentialTargeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid
Chen, F., Wang, Y., Chen, X., Yang, N., & Li, L. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2188487 · Cited by 24 · see citing works
“IL-13 acts as a disease-inducing agent, whereas IL-4 acts as a Th2 response amplifier [10].”
BackgroundDupilumab-associated mycosis fungoides: a cross-sectional study
Hamp, A., Hanson, J., Schwartz, R. A., Lambert, W. C., & Alhatem, A. (2023) · Archives of Dermatological Research · doi:10.1007/s00403-023-02652-z · Cited by 24 · see citing works
“The Food and Drug Administration approved dupilumab in 2017 for the treatment of moderate-to-severe AD in adults, which has been shown to have a strong efficacy in improving cutaneous disease and reducing pruritus [21].”
Diagnosis and Management of Atopic Dermatitis for Primary Care Providers
Fleming, P., Yang, Y. B., Lynde, C. W., O’Neill, B. G., & Lee, K. O. (2020) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2020.04.190449 · Cited by 23 · see citing works
“Dupilumab is a subcutaneously administered human monoclonal antibody for the interleukin-4 receptor-a subunit and is approved for the treat-ment of moderate-severe AD in North America and Europe.”
BackgroundKido‐Nakahara, M., Wang, B., Ohno, F., Tsuji, G., Ulzii, D., Takemura, M., Furue, M., & Nakahara, T. (2020) · Allergy · doi:10.1111/all.14451 · Cited by 22 · see citing works
Felfeli, T., Georgakopoulos, J. R., Jo, C. E., Mimouni, M., Piguet, V., Drucker, A. M., Yeung, J., & Chan, C. C. (2021) · Cornea · doi:10.1097/ico.0000000000002866 · Cited by 22 · see citing works
Tralokinumab for the Treatment of Atopic Dermatitis
Freitas, E., Guttman‐Yassky, E., & Torres, T. R. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00613-8 · Cited by 22 · see citing works
Alessandrello, C., Sanfilippo, S., Minciullo, P., & Gangemi, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25095020 · Cited by 21 · see citing works
Skin microbiota: pathogenic roles and implications in atopic dermatitis
Huang, C., Zhuo, F., Guo, Y., Wang, S., Zhang, K., Li, X., Dai, W., Dou, X., & Yu, B. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1518811 · Cited by 21 · see citing works
German S1 guideline: Contact dermatitis
Dickel, H., Bauer, A., Brehler, R., Mahler, V., Merk, H. F., Neustädter, I., Strömer, K., Werfel, T., Worm, M., & Geier, J. (2022) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14734 · Cited by 20 · see citing works
The contribution of mouse models to understanding atopic dermatitis
Sanjel, B., & Shim, W. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115177 · Cited by 20 · see citing works
Su, C., & Tseng, H. (2021) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.03.007 · Cited by 20 · see citing works
“Common adverse events of dupilumab include nasopharyngitis, upper respiratory tract infections, injection site infections, and conjunctivitis.(8) Throughout the treatment, the patient had a carbuncle on his scalp, which developed 10 months after commencement of his treatment.”
BackgroundThe emerging role of dupilumab in dermatological indications
Napolitano, M., Guida, A. D., Nocerino, M., Fabbrocini, G., & Patruno, C. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1907341 · Cited by 20 · see citing works
“Indeed, AD lesions are characterized by marked increases in some Th2 mediators, such as interleukin (IL)-4, IL-5, IL-13, and IL-31 [2].”
BackgroundBiological agents for severe asthma: the evolution of the at-home self-injection approach
Lombardi, C., Bagnasco, D., & Passalacqua, G. (2020) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000656 · Cited by 19 · see citing works
- Authors
- Gooderham, M. J., Hong, H. C.-H., Eshtiaghi, P., & Papp, K. A.
- Affiliations
- Queen's University (CA)
- University of British Columbia (CA)
- Probity Medical Research (CA)
- Corresponding author
- Gooderham, Melinda J.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 78
- Issue
- 3
- Pages
- S28-S36
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W2789024274
- Cited by
- 343
- References
- 17
- Citations by year
- 2026: 30 · 2025: 39 · 2024: 40 · 2023: 41 · 2022: 47 · 2021: 64 · 2020: 43 · 2019: 28 · 2018: 10
- FWCI
- 39.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of the American Academy of Dermatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bayer
- LEO Pharma
- Sanofi
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- dupilumab, atopic dermatitis, IL-4 receptor alpha antagonist, IL-4/IL-13 signaling, Th2 immune response, topical corticosteroids, biomarkers, adverse events, quality of life, moderate-to-severe atopic dermatitis
- MeSH terms
- Patient Reported Outcome Measures, Antibodies, Monoclonal, Biological Products, Dermatitis, Atopic, Female, Humans, Male, Quality of Life, Severity of Illness Index, Drug Delivery Systems, Treatment Outcome, Clinical Trials, Phase III as Topic, Risk Assessment, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
